Over the course of 2023, we saw plenty of innovation across both in vitro diagnostic (IVD) and diabetes technologies. Source

Nearly 70% of Oklahoma voters polled recently said they paid more for health care and prescription drugs in 2023. Source

Presented by D CEO and Dallas Innovates, honorees include Braemont Capital, Aligned Data Centers, o9 Solutions, LERMA/ Agency, and more. Source

January 24th, 2024 – Good Samaritan Medical Center is proud to announce the launch of its Ion Robotic Bronchoscopy Program, bringing some of the latest technology to lung cancer care. […] Source

From left, George Strickler, of Summa Health Board of Directors; Hemant Taneja, founder of HATCo and CEO of General Catalyst; Dr. Marc Harrison, co-founder and CEO of HATCo; and Dr. Cliff Deveny, president and CEO of Summa Health. Photo courtesy of Summa Health AKRON — Akron-based Summa Health and General Catalyst’s Health Assurance Transformation Corporation…

As we reflect on the flurry of activity in the health care data privacy and security space in 2023 and look ahead to what will continue to be a busy 2024, we are seeing the early stages of federal agency movement to align the regulatory environment with modern health care delivery, cutting-edge technologies, and innovative…

New members and leaders have been named to the ChristianaCare Health System and ChristianaCare Health Services boards, offering valuable expertise for the health system. Salvatore J. “Chip” Rossi Jr. and Paula Swain have been appointed to the ChristianaCare Health System board of directors. “The ChristianaCare Health System Board welcomes the addition of Paula and Chip,…

Key trends such as the resilience of the emerging biopharma space, the complexities of Medicare, and the revolutionary role of data and AI are shaping the future of the industry. Source

BluePearl, Banfield Pet Hospital, and Mars Science & Diagnostics made internal appointments to the leadership roles Source

Global Retinal Biologics Market Global Retinal Biologics Market Dublin, Jan. 25, 2024 (GLOBE NEWSWIRE) — The “Retinal Biologics Global Market Report 2023” report has been added to ResearchAndMarkets.com’s offering. Profound analytics indicate that the market, which was valued at $19.83 billion in 2022, is expected to burgeon to $22.48 billion in 2023 and continue to…